Georgia Chenevix-Trench

Professor
Georgia Chenevix-Trench
FAA FAHMS
Personal details
Born (1959-02-08) 8 February 1959
Nairobi, Kenya

Georgia Chenevix-Trench (born 8 February 1959) is a distinguished Kenyan-Australian cancer researcher who investigates genetic predispositions to cancer.

Early life

Dr. Chenevix-Trench was born in Nairobi, Kenya.[1] Her father, Charles Pocklington Chenevix Trench, was district commissioner of the Northern Frontier District of Kenya during the British colonial period.

Education

Dr. Chenevix-Trench received her undergraduate degree (BSc(Hons)) in 1980 from the department of genetics at Trinity College in Ireland and was subsequently awarded her PhD in 1985 from the department of human genetics at the Medical College of Virginia, USA,[2][3] and in 1986 she commenced her post-doctoral work there. In 1989, she moved to Brisbane, Australia[4] where she started working as a research officer at the Queensland Institute of Medical Research (QIMR). She currently works at the QIMR Berghofer Medical Research Institute, where she heads a cancer genetics research lab.[5]

Distinctions

Dr. Chenevix-Trench was elected to the Australian Academy of Science in 2014, for her work on the genetics of breast, ovarian and other cancers, including showing that mutations in the ATM gene confer moderate risks for breast cancer.[6] In 2015 she was elected Fellow of the Australian Academy of Health and Medical Sciences.[7] She was awarded the Suzanne Cory Medal and Lecture by the Australian Academy of Science in 2022.[8] In 2022, Dr. Chenevix-Trench was awarded the GSK Award for Research Excellence (ARE).[9]

Publications

Dr. Chenevix-Trench has published over 400 papers in peer reviewed journals and has been actively involved in science education and communication.[2] She also has hold numerous patents with other scientists.[10][11]

Selected publications

Mutations of the BRAF gene in human cancer[12]

Patterns of somatic mutation in human cancer genomes[13]

The potential of Senicapoc, a KCNN4 inhibitor, for the prevention and treatment of breast cancer[14]

Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis.[15]

Breast cancer risks associated with missense variants in breast cancer susceptibility genes[16]

References

  1. ^ Who's Who Australian Women (2017), ConnectWeb.
  2. ^ a b "Participant 3 - The Queensland Institute of Medical Research (QIMR)". COGS - Collaborative Oncological Gene-environment Study. Retrieved 21 April 2015.
  3. ^ "Professor Georgia Chenevix-Trench". ACRF Advisory Committee. Retrieved 21 April 2015.
  4. ^ "Forty years of genes and grit: Professor Georgia Chenevix-Trench on science, struggles and staying power". www.qimrb.edu.au. Retrieved 11 February 2026.
  5. ^ "Cancer Genetics - Senior Scientist Professor Georgia Chenevix-Trench". QIMR Berghofer Medical Research Institute. Archived from the original on 14 April 2015. Retrieved 21 April 2015.
  6. ^ "Professor Georgia Chenevix-Trench". Australian Academy of Science. Retrieved 11 February 2025.
  7. ^ "Fellowship | AAHMS – Australian Academy of Health and Medical Sciences". www.aahms.org. Retrieved 25 June 2018.
  8. ^ "2022 awardees". Australian Academy of Science. Retrieved 31 March 2022.
  9. ^ Boecker, Brianna (8 December 2022). "Georgia Chenevix-Trench wins key award for breast cancer research". Women's Agenda. Retrieved 23 September 2024.
  10. ^ WO1997043414A3, Dean, Michael Frederick; Hahn, Heidi & Wicking, Carol et al., "A basal cell carcinoma tumor suppressor gene", issued 12 February 1998 
  11. ^ AU725404B2, Bale, Allen E.; Chenevix-Trench, Georgia & Chidambaram, Abirami et al., "A basal cell carcinoma tumor suppressor gene", issued 12 October 2000 
  12. ^ Davies, Helen; Bignell, Graham R.; Cox, Charles; Stephens, Philip; Edkins, Sarah; Clegg, Sheila; Teague, Jon; Woffendin, Hayley; Garnett, Mathew J.; Bottomley, William; Davis, Neil; Dicks, Ed; Ewing, Rebecca; Floyd, Yvonne; Gray, Kristian (June 2002). "Mutations of the BRAF gene in human cancer". Nature. 417 (6892): 949–954. doi:10.1038/nature00766. ISSN 1476-4687. PMID 12068308.
  13. ^ Greenman, Christopher; Stephens, Philip; Smith, Raffaella; Dalgliesh, Gillian L.; Hunter, Christopher; Bignell, Graham; Davies, Helen; Teague, Jon; Butler, Adam; Stevens, Claire (2007). "Patterns of somatic mutation in human cancer genomes". Nature. 446 (7132): 153–158. Bibcode:2007Natur.446..153G. doi:10.1038/nature05610. PMC 2712719. PMID 17344846.
  14. ^ Xiao, Christos; Miranda, Mariska; Shi, Wei; Beesley, Jonathan; Saunus, Jodi M.; Civitarese, Andrew; Black, Debra M.; Ruppert, Meagan; Pereira, Melrine (28 April 2023). "The potential of Senicapoc, a KCNN4 inhibitor, for the prevention and treatment of breast cancer". bioRxiv 10.1101/2023.04.25.538345.
  15. ^ Escala-Garcia, Maria; Canisius, Sander; Keeman, Renske; Beesley, Jonathan; Anton-Culver, Hoda; Arndt, Volker; Augustinsson, Annelie; Becher, Heiko; Beckmann, Matthias W.; Behrens, Sabine; Bermisheva, Marina; Bojesen, Stig E.; Bolla, Manjeet K.; Brenner, Hermann; Canzian, Federico (5 October 2021). "Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis". Scientific Reports. 11 (1): 19787. doi:10.1038/s41598-021-99409-3. hdl:11343/296838. ISSN 2045-2322. PMC 8492709. PMID 34611289.
  16. ^ Dorling, Leila; Carvalho, Sara; Allen, Jamie; Parsons, Michael T.; Fortuno, Cristina; González-Neira, Anna; Heijl, Stephan M.; Adank, Muriel A.; Ahearn, Thomas U. (2022). "Breast cancer risks associated with missense variants in breast cancer susceptibility genes". Genome Medicine. 14 51. doi:10.1186/s13073-022-01052-8. medRxiv 10.1101/2021.09.02.21262369. PMC 9116026.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.